Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Tagamet Articles

GLOBAL DRUG MARKET: 30 YEARS OF GROWTH

4 January 1993

MERCK & CO EARNINGS ESTIMATES LOWERED

14 December 1992

GASTROINTESTINAL MARKET REVIEW

7 December 1992

EC COURT OVERTURNS UK DRUG PATENT RULING

9 November 1992

RPSGB CANDIDATES FOR POM-TO-P SWITCHING

2 November 1992

RX-TO-OTC SWITCHING FOR SUCCESS

2 November 1992

FOCUS ON IVAX PRODUCT PIPELINE

12 October 1992

ANTI-ULCER DRUG MARKET

5 October 1992

SIDE EFFECTS WITH OMEPRAZOLE?

7 September 1992

SB SETTLES JAPAN PATENT DISPUTE

3 August 1992

SK B injunction

6 July 1992

ZANTAC TOPS MAIL ORDER SALES IN USA

8 June 1992

FUJISAWA HIT BY JAPAN DRUG PRICING MOVES

1 June 1992

H PYLORI TREATMENT: A ROLE FOR OMEPRAZOLE?

25 May 1992

STUDY SUPPORTS ULCER/H PYLORI HYPOTHESIS

11 May 1992

THE UK DRUG INDUSTRYIN REVIEW: 1961-1991

4 May 1992

MOMENTUM OF 1991 CONTINUES AT SB

27 April 1992

EC PHARMA MARKET LURCHES TO COMPLETION

20 April 1992

POST-ELECTION OUTLOOK FOR UK HEALTH SECTOR

20 April 1992

MAINTENANCE ULCER THERAPY CUT URGED

6 April 1992

AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

6 April 1992

AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

6 April 1992

MAINTENANCE ULCER THERAPY CUT URGED

6 April 1992

US GENERIC DRUG MARKET TO 1995

17 February 1992

US OTC DRUGMAKERS A TAKEOVER TARGET

17 February 1992

STOCK MARKET COMMENTARY: EUROPE

10 February 1992

FIRST LAUNCH OF LANSOPRAZOLE

20 January 1992

APOTEK TO BUILD C$50M PHARMA UNIT

6 January 1992

ULCER DRUGS & ALCOHOL

6 January 1992

Showing 201-229 of 229 articles

Go to beginningPrevious
  • 1
  • 2
  • 3
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS